Oxford Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Oxford Asset Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$183K	Buy	+19,271	New	+$150K	0.08%	370
2025 Q3	–	Sell	-66,618	Closed	-$597K	–	466
2025 Q2	$597K	Buy	66,618 +46,401	+230%	+$432K	0.2%	157
2025 Q1	$152K	Buy	20,217 +7,052	+54%	+$56.9K	0.07%	394
2024 Q4	$99K	Buy	+13,165	New	+$99.9K	0.04%	394
2018 Q4	–	Sell	-98,284	Closed	-$747K	–	1779
2018 Q3	$747K	Sell	98,284 -102,637	-51%	-$689K	0.02%	1145
2018 Q2	$1.17M	Sell	200,921 -129,810	-39%	-$715K	0.02%	947
2018 Q1	$1.58M	Buy	330,731 +93,731	+40%	+$482K	0.03%	702
2017 Q4	$1.21M	Buy	237,000 +225,428	+1,948%	+$1.09M	0.03%	840
2017 Q3	$61K	Sell	11,572 -107,102	-90%	-$548K	﹤0.01%	1491
2017 Q2	$660K	Buy	+118,674	New	+$723K	0.01%	1027
2016 Q1	–	Sell	-10,598	Closed	-$110K	–	799
2015 Q4	$110K	Sell	10,598 -222,883	-95%	-$2.22M	﹤0.01%	833
2015 Q3	$2.66M	Buy	+233,481	New	+$3.12M	0.08%	247
2014 Q4	–	Sell	-208,851	Closed	-$2.07M	–	715
2014 Q3	$2.07M	Sell	208,851 -84,754	-29%	-$1.04M	0.05%	365
2014 Q2	$3.73M	Buy	+293,605	New	+$2.86M	0.12%	241

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Oxford Asset Management's BCRX Position: Q1 2026 in Review

Oxford Asset Management opened a new position in BioCryst Pharmaceuticals (BCRX) in Q1 2026: 19,271 shares worth $183K. The stake represents 0.08% of the portfolio and ranks #370 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in BCRX as recently as Q2 2025.

Oxford Asset Management first reported a position in BCRX in Q2 2014 and has held it in 14 quarters since. The position peaked at $3.73M in Q2 2014. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Oxford Asset Management held 19,271 shares of BioCryst Pharmaceuticals worth $183K as of Q1 2026.
BioCryst Pharmaceuticals was a new Oxford Asset Management position in Q1 2026.
BioCryst Pharmaceuticals made up 0.08% of Oxford Asset Management's portfolio in Q1 2026, its #370 holding.
Oxford Asset Management first reported a position in BioCryst Pharmaceuticals in Q2 2014 and has held it in 14 quarters since.
Oxford Asset Management's BioCryst Pharmaceuticals position peaked at $3.73M in Q2 2014.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.